European Journal of Preventive Cardiology Table of Contents for August 2024

New issue alert         Latest impact metrics for European Journal of Preventive Cardiology   We are pleased to share the latest impact metrics for EJPC. The journal was recently awarded a CiteScore™ (Scopus) of 12.5, and a new Impact Factor of 8.4 (Journal Citation Reports™). We invite you to explore the latest breakthroughs published in EJPC and consider the journal as the next outlet for your work.             Volume 31 Issue 10   August 2024       EJPC @ A Glance         EJPC @ a glance: focus issue on lipids and metabolic disorders     Antonin Trimaille, Victor Aboyans       Invited Editorials         A European screening programme for familial hypercholesterolaemia: a call to action     Stephan Gielen, Oliver Weingärtner       Remnant cholesterol: a reliable prognostic marker?     Angela Pirillo, Alberico L Catapano       Full Research Paper     Editor's Choice     Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study     Ji Eun Jun, In-Kyung Jeong, Kyu Jeong Ahn, Ho Yeon Chung, You-Cheol Hwang       Invited Editorial         Hope springs eternal: are we yet ready for a novel paradigm shift in lipid-lowering therapy in primary prevention?     Marc L De Buyzere       Full Research Paper         Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial     Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, Sabina A Murphy, Xinhui Ran ...       Invited Editorial         Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?     Gerald F Watts, Dick C Chan       Full Research Papers         The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction     Yan Zhou, Jasmine Melissa Madsen, Burcu Tas Özbek, Lars Køber, Lia Evi Bang ...       Non-HDL cholesterol and residual cardiovascular risk in statin-treated patients with and without diabetes: the Western Denmark Heart Registry     Malene Kærslund Hansen, Martin Bødtker Mortensen, Kevin Kris Warnakula Olesen, Pernille Gro Thrane, Reimar Wernich Thomsen ...       Invited Editorial         Residual lipidic risk and atherosclerosis: not that residual     Xavier Garcia-Moll       Full Research Paper         Recommended and observed statin use among US adults with and without cancer     Ofer Kobo, Erin D Michos, Ariel Roguin, Rodrigo Bagur, Martha Gulati ...       Invited Editorial         Statins among US adults and cancer: where the future liaises?     Aditya Bhalla, Francois Deharo, Julia Grapsa       Review     Editor's Choice     Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review     Dario Tuccinardi, Mikiko Watanabe, Davide Masi, Lavinia Monte, Luigi Bonifazi Meffe ...       Invited Editorial         Obesity, a disease that deserves clinical awareness     Alexis Elias Malavazos, Valentina Scravaglieri, Federico Boniardi, Chiara Meregalli, Carola Dubini       Full Research Paper         Interaction between type 2 diabetes polygenic risk and physical activity on cardiovascular outcomes     Chia-Lin Lee, Tomohide Yamada, Wei-Ju Liu, Kazuo Hara, Shintaro Yanagimoto ...       Invited Editorial         Variable effect of exercise training programme on cardiovascular outcomes in high-genetic-risk individuals with diabetes     Alexander E Berezin       Full Research Paper         Association between cumulative metabolic risk exposure and cardiovascular disease: a nationwide cohort of over 3.6 million young adults     Heesun Lee, Tae-Min Rhee, Hyo Eun Park, Kyungdo Han, Su-Yeon Choi       Invited Editorial         Metabolic syndrome and premature atherosclerotic cardiovascular disease: insights for the individual and the population     Fernando Yue Cesena       Full Research Paper         Association between lipoprotein(a), LPA genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events     Matthew K Moore, Gregory T Jones, Sally McCormick, Michael J A Williams, Sean Coffey       Research Letters         Exploiting routine laboratory test to identify primary severe hypertriglyceridaemic patients in a large Italian hospital     Chiara Pavanello, Franco Pazzucconi, Marina Parolini, Marta Turri, Giuliana Germana Mombelli ...       Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES     Michael Szarek, Esther Reijnders, Ph Gabriel Steg, J Wouter Jukema, Markus Schwertfeger ...       Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000–23     Christian C Faaborg-Andersen, So Mi Jemma Cho, Pradeep Natarajan, Michael C Honigberg     Unsubscribe       Manage email alerts   Written requests to unsubscribe can be sent to: Journals Marketing, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Our Privacy Policy sets out how Oxford University Press handles your personal information. The content of this email is protected by copyright.